Home > Medication Guide

Medication Guide

In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.

Related Articles

  • Fidaxomicin(Dificid)

    Used for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults and children aged 6 months and older.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:18

  • Ponatinib(Iclusig)

    Chronic Myeloid Leukemia‌ and Acute Lymphoblastic Leukemia‌.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:44

  • Lenvatinib(Lenvima)

    Lenvatinib is indicated for differentiated thyroid carcinoma (DTC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma (EC).【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:5

  • Tucatinib(Tukysa)

    Tucatinib can be used to treat breast cancer and colorectal cancer in adult patients.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:5

  • Vigabatrin(Sabril)

    Vigabatrin is an adjuvant therapy for refractory complex partial epilepsy patients aged 2 years and above.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:10

  • Entrectinib(Rozlytrek)

    Entrectinib is a Broad-spectrum antitumor agents.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:19

  • Upadacitinib(Rinvoq)

    Upadacitinib can regulate abnormal immune responses, alleviate inflammation and symptoms of diseases.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:22

  • Tivozanib(Fotivda)

    Recurrent or refractory advanced renal cell carcinoma (RCC) after two or more previous systemic treatments.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:27

  • Repotrectinib(Augtyro)

    Adult patients with locally advanced or metastatic ROS1 positive non-small cell lung cancer (NSCLC).【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:5

  • Tepotinib(Tepmetko)

    Non small cell lung cancer with MET gene exon 14 mutation positive and unresectable progression and recurrence.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:20

  • Rezurock(Belumosudil mesylate tablets)

    iIndicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease .【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:5

  • Deucravacitinib(Sotyktu)

    Deucravacitinib is suitable for treating plaque psoriasis.【more】
    Article source:Captain MedicineRelease date:2026-01-05Recommended:45

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.

Contact US

Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos

E-mail:laoslucius@gmail.com

Whatsapp:

Lucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved Lucius Pharmaceuticals Lucius

WhatsApp